OS win over enzalutamide in the treatment of prostate cancer at high risk for biochemical recurrence

(MedPage Today) – Berlin – Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in patients with prostate cancer at high risk for biochemical recurrence, according to results…